Aethlon Medical Inc. (AEMD) financial news, and detailed stock charts
Aethlon Medical Inc. (AEMD/AEMD.OB) Stock Summary:
Aethlon Medical, Inc. engages in the research and development of a medical device known as the Hemopurifier that removes harmful substances from the blood. The company’s Hemopurifier platform technology is designed to reduce the presence of infectious viruses and other toxins from human blood. It focuses on developing therapeutic devices to treat acute viral conditions caused by pathogens targeted as potential biological warfare agents, and chronic viral conditions, including HIV/AIDS and Hepatitis-C. The company was founded in 1991 and is headquartered in San Diego, California.www.aethlonmedical.com
3 Employees
Founded in 1991
AETHLON MEDICAL INC (AEMD:OTC Bulletin Board Market)
LAST $0.35 USD
CHANGE TODAY 0.00 0.00%
VOLUME 46.0K
As of 8:10 PM 01/28/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of AETHLON MEDICAL INC (AEMD)
|
OPEN
$0.33
|
PREVIOUS CLOSE
$0.35
|
|
|
DAY HIGH
$0.35
|
DAY LOW
$0.33
|
|
|
52 WEEK HIGH
10/26/09 - $0.73
|
52 WEEK LOW
03/6/09 - $0.12
|
|
|
MARKET CAP
20.5M
|
AVERAGE VOLUME 10 D
124.6K
|
|
|
EPS TTM
$-0.08
|
SHARES OUTSTANDING
58.5M
|
|
|
AEMD Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for AETHLON MEDICAL INC (AEMD)
Aethlon Medical Inc. - Conference Presentation Call
01/19/2010
To review treatment outcomes of dialysis patients infected with Hepatitis-C (HCV), and will discuss the additional use of the HemopurifierR in HIV and Cancer care
Aethlon Medical Inc. - Conference Presentation Call
12/1/2009
To present a corporate overview and provide an update on the company's clinical progress for its lead product, the Hemopurifier, a first-in-class artificial adjunct to the immune system proven to capture infectious viruses and immunosuppressive particles from the human circulatory system
Aethlon Medical Inc. Establishes Exosome Sciences, Inc.
10/22/2009
Aethlon Medical Inc. announced that it has established Exosome Sciences, Inc. as a wholly owned subsidiary of the company. ESI will seek to leverage the recent discovery that the Hemopurifier, a medical device developed by the company as a broad-spectrum therapy against infectious viral pathogens, is effective in capturing exosomes that are secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients. The company will contribute into ESI all exosome-related patents and patents pending.
Aethlon Medical Inc. financial resources
AEMD Competitors
| Company | Last | Change | |
| No competitor information is available for AEMD. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | AEMD | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
AEMD |
||
|
AEMD transactions
| Type Date |
Target |
|
Private Placement
August 24, 2009 |
-- |
More Recent Financial News About Aethlon Medical Inc.
Aethlon Medical Discloses Hepatitis-C (HCV) Treatment Publication
2010-01-27 04:48:02
Quote: Tullis12th International Conference on Dialysis on January 22nd.http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)About Aethlon MedicalAethlon Medical, Inc. creates diagnostic and therapeutic device solutions for infectious disease and cancer.  Our lead product, the Hemopurifier® is the first-in-class medical device to selectively capture circulating viruses and immunosuppressive proteins prior to cell and organ infection.  Human studies have documented the ability of our Hemop...Read article
Aethlon Medical Appoints Douglas Taylor to Exosome Sciences Advisory Board
2010-01-26 02:18:00
Quote: Taylor is credited with the discovery of tumor-secreted exosomes and is a leading published author on the topic.ESI, a wholly owned subsidiary of Aethlon Medical, was recently formed to leverage the discovery that the Hemopurifier®, a medical device being advanced as an adjunct therapy for Hepatitis-C (HCV) and other viral pathogens, is capable of capturing exosomes secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients.The targeted removal of ci...Read article
Aethlon Medical Announces Collaboration to Identify Brain Trauma Biomarkers
2010-01-26 02:18:00
Quote: "Additionally, we have the opportunity to showcase that the scientific advancements underlying our infectious disease and cancer treatment devices provide the basis for new products to discover the presence of biomarkers associated with various medical conditions," concluded Joyce.Aethlon Medicalalso disclosed it will provide SLI with a $25,000 unrestricted educational grant to support educational outreach."Aethlon Medical has presented a wonderful opportunity to advance CTE research," said SLI ...Read article
Aethlon Medical Releases Shareholder Letter
2010-01-26 02:17:59
Quote: 8 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc., (OTC Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders. http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)To our Shareholders:In my September 15th shareholder letter, I indicated that we initiated the program with Bioserv/NextPharma to produce our Hemopurifier® under good manufacturing practice (GMP) requirements set forth in quality system (QS) regulations...Read article
Aethlon Medical to Present at LD MICRO Conference on December 3, 2009
2010-01-26 02:17:59
Quote: Aethlon Medical's Chairman and CEO, James A. Joyce, will present a corporate overview and will provide an update on the company's clinical progress for its lead product, the Hemopurifier®, a first-in-class artificial adjunct to the immune system proven to capture infectious viruses and immunosuppressive particles from the human circulatory system.http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)The LD MICRO Conference brings together 75 presenting companies with over 100 institutio...Read article
Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board
2010-01-26 02:17:57
Quote: 15 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board : AEMD) announced today that Dr. Jeff Schorey and Dr. Wayne Comper have joined the Science Advisory Board of Exosome Sciences, Inc. (ESI). Both Dr. Schorey and Dr. Comper are leading researchers in the exosome field. ESI, a wholly owned subsidiary of Aethlon Medical, was recently formed to leverage the discovery that the Hemopurifier®, a medical device being advanced as an adjunct therapy for Hepatitis-C (HCV) and other vi...Read article
Aethlon Medical Releases Shareholder Update
2010-01-26 02:17:56
Quote: 7 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc., (OTC Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)To our Shareholders:The scientific accomplishments of your Aethlon Medical team in 2009 have set the stage for the initial commercialization of our Hemopurifier® as an adjunct therapy targeted to improve Hepatitis-C virus (HCV) cure rates.  In additio...Read article
RedChip Small-Cap Radio Show Expands to Major Markets
2010-01-26 02:17:56
Quote: (NYSE Amex:IGC); RXi Pharmaceuticals Corporation (Nasdaq: - ); Aethlon Medical, Inc. (OTCBB: - ); China Linen Textile Industry, Ltd. (OTCBB: - ); L&L International Holdings, Inc. (OTCBB: - ); Alter NRG Corp. (TSX: -To listen to archived shows, please visit:RedChip Small-Cap Radio is a radio news forum that addresses general market and small-cap news and interviews from CEOs and executives of prominent small-cap companies. The program features exclusive CEO interviews conducted by Gary McKenz...Read article
RedChip Visibility Issues Research Update on Aethlon Medical
2010-01-26 02:17:55
Quote: During the final months of the year, the bulk of visible progress took place in improving manufacturing processes in ways necessary for broad commercialization."
Webber continued "We continue to rate Aethlon Medical a Speculative Buy with a 12-month price target of $1.00 per share. According to management, talks continue with potential partners. As it is not clear when to expect the next substantial increment of clinical data, we consider news of a partnership, should that occur, the potential ...Read article
RedChip Visibility Issues Research Update on Aethlon Medical
2010-01-14 04:28:05
Quote: During the final months of the year, the bulk of visible progress took place in improving manufacturing processes in ways necessary for broad commercialization."
Webber continued "We continue to rate Aethlon Medical a Speculative Buy with a 12-month price target of $1.00 per share. According to management, talks continue with potential partners. As it is not clear when to expect the next substantial increment of clinical data, we consider news of a partnership, should that occur, the potential ...Read article
Aethlon Medical Releases Shareholder Update
2010-01-08 01:31:00
Quote: 7 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc., (OTC Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)To our Shareholders:The scientific accomplishments of your Aethlon Medical team in 2009 have set the stage for the initial commercialization of our Hemopurifier® as an adjunct therapy targeted to improve Hepatitis-C virus (HCV) cure rates.  In additio...Read article
Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board
2009-12-23 02:37:19
Quote: 15 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board : AEMD) announced today that Dr. Jeff Schorey and Dr. Wayne Comper have joined the Science Advisory Board of Exosome Sciences, Inc. (ESI). Both Dr. Schorey and Dr. Comper are leading researchers in the exosome field. ESI, a wholly owned subsidiary of Aethlon Medical, was recently formed to leverage the discovery that the Hemopurifier®, a medical device being advanced as an adjunct therapy for Hepatitis-C (HCV) and other vi...Read article
Aethlon Medical Releases Shareholder Letter
2009-12-09 02:03:41
Quote: 8 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc., (OTC Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders. http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)To our Shareholders:In my September 15th shareholder letter, I indicated that we initiated the program with Bioserv/NextPharma to produce our Hemopurifier® under good manufacturing practice (GMP) requirements set forth in quality system (QS) regulations...Read article
Aethlon Medical to Present at LD MICRO Conference on December 3, 2009
2009-12-02 01:10:19
Quote: Aethlon Medical's Chairman and CEO, James A. Joyce, will present a corporate overview and will provide an update on the company's clinical progress for its lead product, the Hemopurifier®, a first-in-class artificial adjunct to the immune system proven to capture infectious viruses and immunosuppressive particles from the human circulatory system.http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)The LD MICRO Conference brings together 75 presenting companies with over 100 institutio...Read article
Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
2009-11-30 07:10:05
Quote: The Aethlon Hemopurifier® is the first-in-class medical device able to selectively remove viruses and immunosuppressive proteinsfrom the bloodstream.In HCV care, the device targets to improve patient cure rates as an adjunct to accelerate and enhance the performance of current and future iterations of standard of care drug therapy.About ASNwww.asn-online.org for additional detail.About Aethlon Medicalwww.aethlonmedical.com.Certain of the statements herein may be forward-looking and involve r...Read article
Aethlon Medical Announces BIOCOM Conference Presentation
2009-11-30 07:10:05
Quote: AEMDNewswww.aethlonmedical.com/about/location.htm.http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)http://www.biocom.org.About Aethlon Medicalwww.aethlonmedical.com.Jon@redchip.comjj@aethlonmedical.comjfrakes@aethlonmedical.com
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievem...Read article
Aethlon Medical Establishes Exosome Sciences, Inc.
2009-11-30 07:10:04
Quote: (ESI) as a wholly owned subsidiary of the Company.ESI will seek to leverage the recent discovery that the Hemopurifier®, a medical device developed by Aethlon Medical as a broad-spectrum therapy against infectious viral pathogens, is effective in capturing exosomes that are secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients.Aethlon Medical, Inc. will contribute into ESI all exosome-related patents and patents pending.http://www.newscom.com/cg...Read article
Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
2009-11-30 07:10:04
Quote: AEMDNewsinvitro studies, the Hemopurifier® removed 68% of H1N1 virus from blood plasma in 30 minutes, 80% of the virus in two hours, and a 96% reduction of H1N1 was observed at six hours.The studies were performed by third party researchers approved by the United States Department of Health and Human Services (HHS) to house and conduct research on the current pandemic strains of H1N1 virus.http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)http://www.cdc.gov/H1N1flu.Previous studies ...Read article
Aethlon Medical Discloses Live Webcast of Today's BIOCOM Presentation
2009-11-30 07:10:03
Quote: For more information on BIOCOM or the Southern California biotechnology and medical device community, please visit the organization's website at Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier® represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier® seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum tre...Read article
Aethlon Medical Appoints Douglas Taylor to Exosome Sciences Advisory Board
2009-11-30 07:10:02
Quote: Taylor is credited with the discovery of tumor-secreted exosomes and is a leading published author on the topic.ESI, a wholly owned subsidiary of Aethlon Medical, was recently formed to leverage the discovery that the Hemopurifier®, a medical device being advanced as an adjunct therapy for Hepatitis-C (HCV) and other viral pathogens, is capable of capturing exosomes secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients.The targeted removal of ci...Read article
Would you like to leave a comment about Aethlon Medical Inc. AEMD/AEMD.OB
Find out what social network information about Aethlon Medical Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Aethlon Medical Inc.'s Stock there is more great Microcap and Stock Market information available at Realpennies.com